首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1562307

中東和非洲人類疫苗佐劑市場預測至 2030 年 - 區域分析 - 按類型、應用（流感、肝炎、人類乳突病毒等）和最終用戶

Middle East & Africa Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 109 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年中東和非洲人用疫苗佐劑市場價值為4,918萬美元，預計2030年將達到1,1937萬美元；預計2022年至2030年複合年成長率為11.7%。

慢性病盛行率上升提振中東和非洲人類疫苗佐劑市場

慢性病盛行率的上升推動了對疫苗佐劑的需求。疫苗中添加佐劑以增強功效和身體的免疫反應。它們透過刺激更強、更持久的免疫反應來幫助提高疫苗的有效性。隨著預防和管理慢性病的疫苗需求持續成長，佐劑的需求也隨之增加。心血管疾病、癌症、糖尿病和呼吸系統疾病等慢性疾病在全球呈現上升趨勢。據世界衛生組織稱，與非傳染性疾病相關的死亡最多的是心血管疾病，每年約造成 1700 萬人死亡，其次是癌症、慢性呼吸道疾病和糖尿病（包括與腎臟相關的死亡）。此外，根據世界心臟聯盟的數據，高膽固醇每年導致 440 萬人死亡，約 24% 的心血管相關死亡可歸因於高低密度脂蛋白 (LDL) 膽固醇。因此，慢性病負擔的增加導致對能夠預防或控制這些疾病的疫苗的需求不斷成長。肝炎的盛行率也在增加。肝炎疫苗中的佐劑旨在引發強大而持久的免疫力，特別是對標準疫苗配方反應不佳的人群，例如患有潛在疾病或與年齡相關的免疫衰老的人群。據世界衛生組織稱，全世界有超過 3.5 億人患有乙型或丙型肝炎。根據世界衛生組織的一項研究，到 2030 年，低收入和中等收入國家估計可透過疫苗接種預防 450 萬人因肝炎而過早死亡。因此，慢性病盛行率的增加推動了中東和非洲人類疫苗佐劑市場的成長。

中東和非洲人用疫苗佐劑市場概況

作為國家轉型計劃的一部分，沙烏地阿拉伯計劃將 40% 的製藥業在地化，並減少其進口依賴。在沙烏地阿拉伯，經濟和社會變化導致久坐生活方式的轉變，導致肥胖盛行率不斷上升，代謝症候群預計也會增加。此外，患者缺乏疾病意識和關於疾病傳播的知識，增加了該國傳染病的盛行率。例如，根據2023 年PubMed 發表的一項研究《沙烏地阿拉伯和阿拉伯聯合大公國的乙型肝炎病毒感染：公共衛生挑戰及其補救措施》，即使在實施了乙型肝炎病毒治療和管理後，沙烏地阿拉伯在乙型肝炎病毒治療和管理方面仍面臨嚴峻挑戰大規模疫苗接種計畫。同樣，根據 ICO/IARC 資訊中心 2023 年 HPV 和癌症報告，沙烏地阿拉伯有 1,070 萬 15 歲及以上女性人口，有 HPV 相關子宮頸癌的風險。因此，阿拉伯聯合大公國傳染病日益普及加劇了對人類疫苗佐劑的需求。近年來，沙烏地阿拉伯王國在醫療保健和製藥領域進行了大量投資，旨在增強國內生產、研發能力。這項策略重點為潛在成長奠定了基礎，影響了中東和非洲人類疫苗佐劑市場。在沙烏地阿拉伯，法赫德國王醫療城、費薩爾國王專科醫院和研究中心以及衛生部等機構積極參與推進醫療保健研究，包括與疫苗和佐劑相關的研究。對研究設施和醫療基礎設施的此類投資標誌著我們致力於為全球疫苗領域做出貢獻。它還預計將為佐劑研究和開發進步鋪平道路。

中東和非洲人類疫苗佐劑市場收入及 2030 年預測（百萬美元）

中東和非洲人用疫苗佐劑市場區隔

中東和非洲人疫苗佐劑市場按類型、應用、最終用戶和國家分類。

根據類型，中東和非洲人用疫苗佐劑市場分為顆粒佐劑、乳液佐劑、組合佐劑等。 2022 年，顆粒助劑領域佔最大的市場佔有率。

從應用來看，中東和非洲人疫苗佐劑市場分為流感、肝炎、人類乳突病毒（HPV）等。 2022 年，流感細分市場佔據最大市場。

以最終用戶分類，中東和非洲人疫苗佐劑市場分為製藥和生技公司、CMO 和 CRO 等。 2022 年，製藥和生物技術公司領域佔據最大的市場佔有率。

依國家分類，中東和非洲人疫苗佐劑市場分為沙烏地阿拉伯、南非、阿拉伯聯合大公國以及中東和非洲其他地區。 2022年，沙烏地阿拉伯在中東和非洲人類疫苗佐劑市場佔有率中佔據主導地位。

Novartis AG、CSL Ltd、Seppic SA、Croda International Plc、Novavax Inc 和 Phibro Animal Health Corp 是中東和非洲人類疫苗佐劑市場的一些領先公司。

The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body's immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally. According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ~17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The prevalence of hepatitis is also increasing. Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030 through vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the Middle East & Africa human vaccine adjuvants market.

Middle East & Africa Human Vaccine Adjuvants Market Overview

Saudi Arabia has planned to localize 40% of the pharmaceutical sector and reduce its import dependence as part of its National Transformation Program. In Saudi Arabia, economic and social changes have led to a shift in sedentary lifestyles, leading to an increasing prevalence of obesity and a projected rise in metabolic syndrome. Furthermore, a lack of disease awareness and knowledge about disease transmission among patients has increased the prevalence of infectious diseases in the country. For instance, according to a study, "Hepatitis B virus infection in Saudi Arabia and the UAE: Public health challenges and their remedial measures," published in PubMed in 2023, Saudi Arabia faces critical challenges in Hepatitis B virus treatment and management even after implementing a mass vaccination program. Similarly, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Saudi Arabia has a population of 10.7 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Thus, the increasing prevalence of infectious diseases in the UAE fuels the demand for human vaccine adjuvants. In recent years, the Kingdom of Saudi Arabia has invested substantially in the healthcare and pharmaceutical sectors, aiming to enhance domestic production, research, and development capabilities. This strategic focus has set the stage for potential growth, influencing the Middle East & Africa human vaccine adjuvants market. In Saudi Arabia, the King Fahd Medical City, King Faisal Specialist Hospital & Research Centre, and the Ministry of Health are among the institutions actively involved in advancing healthcare research, including those related to vaccines and adjuvants. Such investment in research facilities and medical infrastructure signals a commitment to contributing to the global vaccine landscape. It is also projected to pave the way for adjuvant research and development advancements.

Middle East & Africa Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Human Vaccine Adjuvants Market Segmentation

The Middle East & Africa human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Middle East & Africa human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Middle East & Africa human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Middle East & Africa human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Middle East & Africa human vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa human vaccine adjuvants market share in 2022.

Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp are some of the leading companies operating in the Middle East & Africa human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Middle East & Africa Market Analysis

5.1 Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Middle East & Africa Human Vaccine Adjuvants Market Forecast Analysis

6. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human Papilloma Virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Human Vaccine Adjuvants Market - Country Analysis

9.1 Middle East & Africa
- 9.1.1 Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 South Africa Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 South Africa Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 South Africa Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 CSL Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Seppic SA
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Croda International Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novavax Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Phibro Animal Health Corp
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation
Table 2. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 19. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)